Log in

Start Your Membership Now

On November 15, 2017, the U.S. Food and Drug Administration (FDA) granted marketing approval for the first prescription device intended to treat physical symptoms of opioid withdrawal during a supervised addiction treatment program. The goal is to help users manage the acute withdrawal symptoms so that they continue with treatment, including the transition to medication assisted treatment (MAT). The device, created by Innovative Health Solutions, Inc., is called the Bridge Neurostimulation System (NSS-2 BRIDGE).

The small NSS-2 BRIDGE device is an electrical nerve field stimulator that is attached behind the ear with adhesives; the electrodes are attached . . .

Want To Read More? Log In Or Become A Paid Member
Resource Available For Paid OPEN MINDS Circle Members Only
Not a paid member? Don't miss out! Sign up today and receive unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!
Log In
If you are already a paid member, log in to your account to access this resource and more. If you are a free member, you will need to upgrade to a paid membership before accessing this resource.

Become A Paid Member
If you are not yet a paid member, learn more about the OPEN MINDS Circle Market Intelligence Service Membership on our website, reach out to our team at info@openminds.com, or call us at 877-350-6463.

Tagged As: